{"Abbreviation":"A4","Aliases":["Androst-4-ene-3,17-dione","4-Androstene-3,17-dione","4-Androstenedione","Androtex","3,17-Dioxoandrost-4-ene","Fecundin","SKF 2170","Δ-4-Androsten-3,17-dione","17-Ketotestosterone","Δ-(sup4)-Androsten-3,17-dione"],"Boiling Point":"Decomposes at 200 °C before boiling","CAS":"63-05-8","ChEBI":"CHEBI:16422","ChEMBL":"CHEMBL274826","ChemicalClasses":["steroid"],"Chirality":"absolute","Color/Form":"Crystals from hexane","Decomposition":"When heated to decomposition it emits acrid smoke and irritating fumes.","Density":"1.18 g/cu cm at 20 °C (GLP compliance study) g/cm\u003csup\u003e3\u003c/sup\u003e","Dosing Info":[],"Drug Warnings":"Androstenedione and related molecules, if given in sufficient quantities and for sufficient duration, are likely to cause androgenic (and thus anabolic) or estrogenic effects in humans. ...  Children and adolescents are particularly vulnerable to irreversible effects of androstenedione via its conversion to active sex steroids. These effects include disruption of normal sexual development, specifically virilization in girls associated with severe acne, excessive body and facial hair, deepening of the voice, permanent enlargement of the clitoris, disruption of the menstrual cycle, and infertility. The conversion to estrogens can cause feminization of boys, with breast enlargement and testicular atrophy. In girls, exposure to excess estrogens may confer long-term increased risk for breast and uterine cancer. Finally, in boys and girls, the combined effects of excessive androgens and estrogens can induce premature puberty, early closure of the growth plates of long bones, resulting in significant compromise of adult stature.","DrugClasses":[],"EINECS":"200-554-5","EliminationHalfLife":"","European Community (EC) Number":"200-554-5","HMDB ID":"HMDB0000053","HeavyAtomCount":21,"Human Drugs":"Pharmaceuticals","IUPACName":"(8R,9S,10R,13S,14S)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione","InChI":"InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1","InChIKey":"AEMFNILZOJDQLW-QAGGRKNESA-N","Melting Point":"173-174 °C (crystals from hexane)","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e26\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"286.4 g/mol","Opticalactivity":"UNSPECIFIED","Physical Description":"Solid","PrevSalts":[],"PubChemId":6128,"Record Description":["Androstenedione can cause cancer according to The National Toxicology Program.","Androst-4-ene-3,17-dione is a 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17-oxo steroid, an androstanoid and a 3-oxo-Delta(4) steroid.","A delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.","Androstenedione has been reported in Locusta migratoria, Homo sapiens, and other organisms with data available.","Therapeutic Androstenedione is a potent androgenic prohormone that is a direct precursor of testosterone and used as a supplement to increase plasma testosterone levels and muscle anabolism. (NCI)","Androstenedione is a steroid hormone synthesized by the adrenal glands and the gonads from either 17-alpha-hydroxyprogesterone or dehydroepiandrosterone and is a precursor of testosterone.","Androstenedione is a delta-4 19-carbon steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol. It is the common precursor of male and female sex hormones. Some androstenedione is also secreted into the plasma, and may be converted in peripheral tissues to testosterone and estrogens. Androstenedione originates either from the conversion of dehydroepiandrosterone or from 17-hydroxyprogesterone. It is further converted to either testosterone or estrone. The production of adrenal androstenedione is governed by ACTH, while production of gonadal androstenedione is under control by gonadotropins.","A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.","See also: Androstenediol (annotation moved to).","Androstenedione can cause cancer according to The National Toxicology Program.","Androst-4-ene-3,17-dione is a 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17-oxo steroid, an androstanoid and a 3-oxo-Delta(4) steroid.","LiverTox|HDS: Anabolic steroid|Body building|Anabolic steroid"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Androstenedione","Name":"Androstenedione","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q411064","Name":"Androstenedione","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01536","Name":"Androstenedione","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/6128","Name":"Androstenedione","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL274826","Name":"Androstenedione","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16422","Name":"Androstenedione","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=63-05-8","Name":"Androstenedione","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0000053","Name":"Androstenedione","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C00280","Name":"Androstenedione","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/409J2J96VR","Name":"Androstenedione","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID8024523","Name":"Androstenedione","Sub":false}]}],"SMILES":"C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C","Scheduling":[{"gov":"United States","schedule":"Schedule III substance"}],"Solubility":"In water, 57.3 mg/L at 25 °C, pH 7.3; 40 mg/L at 37 °C, pH 7.4","Stability/Shelf Life":"In surface waters, two of the most commonly observed androgenic steroid hormones are androstenedione (AD) and testosterone (T). This study compares the photodegradation of dilute (\u003c10 ug/L) aqueous solutions of AD and T in natural sunlight, and evaluates the endocrine-disrupting potential of the resulting solutions. This study also examines the effect of dissolved organic matter (DOM) on AD photodegradation. During spring and summer at Henderson, NV, USA (latitude 36.04 deg N), AD and T underwent direct photodegradation, with half-lives ranging from 3.7 to 10.8 hr. In three model DOM solutions, AD's half-life increased by 11% to 35%. Using screening factors to eliminate DOM's inner filter effect, quantum yield calculations suggested that light screening was primarily responsible for AD's increased half-life, and that physical quenching further inhibited AD's photodegradation in two out of three DOM solutions. In vitro androgenic activity of the AD and T solutions decreased approximately as fast as AD and T were removed, suggesting that solar photodegradation reduces the risk of endocrine disruption in surface waters impacted by AD or T, subject to continuing inputs. Reduced in vitro androgenic activity appears to be related to steroid ring cleavage and the formation of highly oxidized photoproducts.","StoreUNII":["409J2J96VR"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="71.051mm" version="1.2" viewBox="0 0 106.473 71.051" width="106.473mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#000000" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="72.0" stroke="none" width="107.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <path class="bond" d="M42.082 45.108h.7l1.75 -20.117h-2.1h-2.1z" id="mol1bnd1" stroke="none"/>
                  
            <line class="bond" id="mol1bnd2" x1="42.432" x2="29.224" y1="45.108" y2="37.488"/>
                  
            <line class="bond" id="mol1bnd3" x1="29.224" x2="16.016" y1="37.488" y2="45.108"/>
                  
            <line class="bond" id="mol1bnd4" x1="16.016" x2="16.016" y1="45.108" y2="60.348"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="17.236" x2="6.707" y1="61.051" y2="67.133"/>
                        
                <line x1="16.016" x2="5.487" y1="58.94" y2="65.021"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.707000000000001" x2="11.9715" y1="67.133" y2="64.092"/>
                <line class="hi" stroke="#FF0D0D" x1="5.487" x2="10.7515" y1="65.021" y2="61.9805"/>
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="16.016" x2="29.224" y1="60.348" y2="67.968"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="29.224" x2="42.432" y1="67.968" y2="60.348"/>
                        
                <line x1="29.224" x2="39.994" y1="65.153" y2="58.94"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="42.432" x2="42.432" y1="45.108" y2="60.348"/>
                  
            <line class="bond" id="mol1bnd9" x1="42.432" x2="55.64" y1="60.348" y2="67.968"/>
                  
            <path class="bond" d="M55.657 68.311c-.127 -.0 -.26 -.063 -.32 -.168c-.087 -.152 -.023 -.391 .128 -.478l13.208 -7.62c.048 -.048 .105 -.068 .163 -.068c.125 -.0 .256 .092 .315 .196c.088 .152 .024 .391 -.128 .478l-13.208 7.62c-.047 .027 -.102 .04 -.158 .04z" id="mol1bnd10" stroke="none"/>
                  
            <line class="bond" id="mol1bnd11" x1="68.848" x2="68.848" y1="60.348" y2="45.108"/>
                  
            <line class="bond" id="mol1bnd12" x1="68.848" x2="55.64" y1="45.108" y2="37.488"/>
                  
            <line class="bond" id="mol1bnd13" x1="42.432" x2="55.64" y1="45.108" y2="37.488"/>
                  
            <line class="bond" id="mol1bnd14" x1="55.64" x2="55.64" y1="37.488" y2="22.248"/>
                  
            <path class="bond" d="M55.657 22.591c-.127 -.0 -.26 -.063 -.32 -.168c-.087 -.152 -.023 -.391 .128 -.478l13.208 -7.62c.048 -.048 .105 -.068 .163 -.068c.125 -.0 .256 .092 .315 .196c.088 .152 .024 .391 -.128 .478l-13.208 7.62c-.047 .027 -.102 .04 -.158 .04z" id="mol1bnd15" stroke="none"/>
                  
            <line class="bond" id="mol1bnd16" x1="68.848" x2="82.056" y1="14.628" y2="22.248"/>
                  
            <line class="bond" id="mol1bnd17" x1="82.056" x2="82.056" y1="22.248" y2="37.488"/>
                  
            <line class="bond" id="mol1bnd18" x1="68.848" x2="82.056" y1="45.108" y2="37.488"/>
                  
            <line class="bond" id="mol1bnd19" x1="82.056" x2="96.483" y1="37.488" y2="42.161"/>
                  
            <line class="bond" id="mol1bnd20" x1="96.483" x2="105.424" y1="42.161" y2="29.868"/>
                  
            <line class="bond" id="mol1bnd21" x1="105.424" x2="96.483" y1="29.868" y2="17.574"/>
                  
            <line class="bond" id="mol1bnd22" x1="82.056" x2="96.483" y1="22.248" y2="17.574"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="95.05" x2="98.795" y1="18.038" y2="6.522"/>
                        
                <line x1="97.369" x2="101.114" y1="18.792" y2="7.276"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="98.795" x2="96.9225" y1="6.522" y2="12.280000000000001"/>
                <line class="hi" stroke="#FF0D0D" x1="101.114" x2="99.2415" y1="7.276" y2="13.034"/>
            </g>
                  
            <path class="bond" d="M81.708 22.211l.696 .074l3.338 -14.973l-2.089 -.22l-2.088 -.22z" id="mol1bnd24" stroke="none"/>
                  
            <path class="bond" d="M69.198 45.108h-.7l-1.308 11.39h1.658h1.658z" id="mol1bnd25" stroke="none"/>
                  
            <g class="bond" id="mol1bnd26">
                        
                <line x1="55.29" x2="55.99" y1="37.488" y2="37.488"/>
                        
                <line x1="55.04" x2="56.24" y1="35.311" y2="35.311"/>
                        
                <line x1="54.79" x2="56.49" y1="33.134" y2="33.134"/>
                        
                <line x1="54.54" x2="56.74" y1="30.956" y2="30.956"/>
                        
                <line x1="54.29" x2="56.99" y1="28.779" y2="28.779"/>
                        
                <line x1="54.04" x2="57.24" y1="26.602" y2="26.602"/>
                      
            </g>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="82.406" x2="81.706" y1="37.488" y2="37.488"/>
                        
                <line x1="82.656" x2="81.456" y1="39.665" y2="39.665"/>
                        
                <line x1="82.906" x2="81.206" y1="41.842" y2="41.842"/>
                        
                <line x1="83.156" x2="80.956" y1="44.019" y2="44.019"/>
                        
                <line x1="83.406" x2="80.706" y1="46.196" y2="46.196"/>
                        
                <line x1="83.656" x2="80.456" y1="48.374" y2="48.374"/>
                      
            </g>
                  
            <path class="atom" d="M5.078 67.967q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 67.967q-.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M103.455 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM99.591 3.078q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm20" stroke="none"/>
                  
            <path class="atom" d="M70.72 62.798h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm22" stroke="none"/>
                  
            <path class="atom" d="M57.512 24.698h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm23" stroke="none"/>
                  
            <path class="atom" d="M83.928 55.178h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm24" stroke="none"/>
                
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Androstenedione is included in the database.","Title":"Androstenedione","UNII":"409J2J96VR","Wikidata":"Q411064","Wikipedia":"Androstenedione","XLogP":2.7}